Drug intelligence / Profile preview

KV10ra

Development stage: Preclinical
Lead developer: Kensana Health
Modality: Small Molecules

Overview

KV10ra is a preclinical-stage phytopharmaceutical candidate being developed by Kensana Health for the treatment of rheumatoid arthritis. It is designed to modulate the endocannabinoid system (ECS) to address the inflammatory processes and pain associated with the disease. As a cannabinoid-based therapeutic, KV10ra aims to leverage the anti-inflammatory properties of the ECS to provide a novel treatment option for patients with inflammatory arthritis. The program is currently in the preclinical phase of development.

Beyond the preview

Go deeper on KV10ra.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KV10ra.

Explore the full profile